CN115023435B - 免疫治疗化合物和方法 - Google Patents

免疫治疗化合物和方法

Info

Publication number
CN115023435B
CN115023435B CN202080079445.7A CN202080079445A CN115023435B CN 115023435 B CN115023435 B CN 115023435B CN 202080079445 A CN202080079445 A CN 202080079445A CN 115023435 B CN115023435 B CN 115023435B
Authority
CN
China
Prior art keywords
seq
amino acid
cells
compound
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080079445.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115023435A (zh
Inventor
D·A·瓦列拉
J·S·米勒
M·菲里西斯
M·施勒德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GT Biopharma Inc
University of Minnesota System
Original Assignee
GT Biopharma Inc
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GT Biopharma Inc, University of Minnesota System filed Critical GT Biopharma Inc
Publication of CN115023435A publication Critical patent/CN115023435A/zh
Application granted granted Critical
Publication of CN115023435B publication Critical patent/CN115023435B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN202080079445.7A 2019-09-16 2020-09-15 免疫治疗化合物和方法 Active CN115023435B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Publications (2)

Publication Number Publication Date
CN115023435A CN115023435A (zh) 2022-09-06
CN115023435B true CN115023435B (zh) 2026-03-27

Family

ID=74883667

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079445.7A Active CN115023435B (zh) 2019-09-16 2020-09-15 免疫治疗化合物和方法

Country Status (10)

Country Link
US (1) US20220324972A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031565A4 (cg-RX-API-DMAC7.html)
JP (2) JP7773152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220087441A (cg-RX-API-DMAC7.html)
CN (1) CN115023435B (cg-RX-API-DMAC7.html)
AU (1) AU2020350524B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154158A1 (cg-RX-API-DMAC7.html)
IL (1) IL291343A (cg-RX-API-DMAC7.html)
WO (1) WO2021055342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697736A (zh) * 2015-10-06 2018-10-23 明尼苏达大学董事会 治疗性组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697736A (zh) * 2015-10-06 2018-10-23 明尼苏达大学董事会 治疗性组合物和方法

Also Published As

Publication number Publication date
KR20220087441A (ko) 2022-06-24
WO2021055342A1 (en) 2021-03-25
BR112022004712A2 (pt) 2022-06-14
JP2026021424A (ja) 2026-02-10
EP4031565A4 (en) 2023-10-25
AU2020350524A1 (en) 2022-04-21
EP4031565A1 (en) 2022-07-27
JP7773152B2 (ja) 2025-11-19
JP2022548145A (ja) 2022-11-16
US20220324972A1 (en) 2022-10-13
IL291343A (en) 2022-05-01
CA3154158A1 (en) 2021-03-25
AU2020350524B2 (en) 2026-07-09
CN115023435A (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
CN107849148B (zh) 三特异性结合蛋白质及使用方法
CN105121474B (zh) 融合免疫调节蛋白及其制备方法
EP4019550A1 (en) Anti-pd-l1 single domain antibodies
KR102897353B1 (ko) Nk 관여 분자 및 이의 사용 방법
CA3183711A1 (en) B7h3-targeting proteins and methods of use thereof
WO2010107658A2 (en) Methods and compositions for bi-specific targeting of cd19/cd22
CN115023435A (zh) 免疫治疗化合物和方法
TW202237664A (zh) 免疫調節及抗腫瘤相關奈米抗體暨其核酸編碼序列及其應用
AU2017214685B2 (en) EGFL6 specific monoclonal antibodies and methods of their use
CN109627340B (zh) Cd3和prlr双特异性抗体及其构建与应用
US12269887B2 (en) Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
KR20230126714A (ko) 메소텔린 결합 분자 및 이의 사용
CN114929745B (zh) Clec12a抗体片段序列和方法
EP4435006A1 (en) Bispecific antibody and use thereof
WO2017059270A1 (en) Deimmunized therapeutic compositions and methods
WO2017138471A1 (ja) 抗イヌcd70モノクローナル抗体
US20240317831A1 (en) Nk cell engager molecules and methods of use
CN115785269B (zh) 抗pd-l1的抗体及其应用
WO2025136820A9 (en) Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use
WO2025256479A1 (zh) 一种融合蛋白及其用途
KR20230125809A (ko) Fap 결합 분자 및 이의 사용
HK40117294A (en) Bispecific antibody and use thereof
EA042513B1 (ru) Psma-нацеленные триспецифические белки и способы их применения
HK1263031A1 (zh) 去免疫的治疗性组合物和方法
HK1217343B (en) Fusion immunomodulatory proteins and methods for making same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant